Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 5961974, 6 pages
https://doi.org/10.1155/2018/5961974
Research Article

PTX3: A Potential Biomarker in Thyroid Associated Ophthalmopathy

1Department of Ophthalmology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
2Department of Ophthalmology, Shanghai Zhabei District Central Hospital, Shanghai 200003, China

Correspondence should be addressed to Jinwei Cheng; moc.361@evawnnij and Ruili Wei; moc.621@iewiliur

Received 3 October 2017; Revised 17 January 2018; Accepted 23 January 2018; Published 20 February 2018

Academic Editor: Yoshifumi Saisho

Copyright © 2018 Pei Mou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Sawicka-Gutaj, T. Bednarczuk, J. Daroszewski et al., “GO-QOL—Disease-specific quality of life questionnaire in Graves' orbitopathy,” Endokrynologia Polska, vol. 66, no. 4, pp. 362–366, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Menconi, C. Marcocci, and M. Marinò, “Diagnosis and classification of Graves' disease,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 398–402, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. M. N. Stan and R. S. Bahn, “Risk factors for development or deterioration of Graves' ophthalmopathy.,” Thyroid, vol. 20, no. 7, pp. 777–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Alibaz-Oner, K. Aksu, S. P. Yentur, G. Keser, G. Saruhan-Direskeneli, and H. Direskeneli, “Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow–up,” Clinical and Experimental Rheumatology, vol. 34, pp. S73–S76, 2016. View at Google Scholar · View at Scopus
  5. P. Cieślik and A. Hrycek, “Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus,” Autoimmunity, vol. 48, no. 4, pp. 242–250, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Iwata, A. Yoshizaki, F. Ogawa et al., “Increased serum pentraxin 3 in patients with systemic sclerosis,” The Journal of Rheumatology, vol. 36, no. 5, pp. 976–983, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Peri, M. Introna, D. Corradi et al., “PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans,” Circulation, vol. 102, no. 6, pp. 636–641, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sahin, A. Adrovic, K. Barut et al., “Pentraxin-3 levels are associated with vasculitis and disease activity in childhood-onset systemic lupus erythematosus,” Lupus, vol. 26, no. 10, pp. 1089–1094, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Uzun, M. Ozari, M. Gursu et al., “Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3,” Renal Failure, vol. 38, no. 8, pp. 1193–1198, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. H. S. Yang, J. E. Woo, S. J. Lee, S. H. Park, and J. M. Woo, “Elevated plasma pentraxin 3 levels are associated with development and progression of diabetic retinopathy in korean patients with type 2 diabetes mellitus,” Investigative Ophthalmology & Visual Science, vol. 55, no. 9, pp. 5989–5997, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Brügger-Andersen, V. Pönitz, F. Kontny et al., “The long pentraxin 3 (PTX3): A novel prognostic inflammatory marker for mortality in acute chest pain,” Thrombosis and Haemostasis, vol. 102, no. 3, pp. 555–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Garianda, E. Hirsch, S. Bozza et al., “Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response,” Nature, vol. 420, no. 6912, pp. 182–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Mantovani, C. Garlanda, and B. Bottazzi, “Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity,” Vaccine, vol. 21, no. 2, pp. S43–S47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Bartalena, L. Baldeschi, A. Dickinson et al., “Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO,” European Journal of Endocrinology, vol. 158, no. 3, pp. 273–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. P. Mourits, M. F. Prummel, W. M. Wiersinga, and L. Koornneef, “Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy,” Clinical Endocrinology, vol. 47, no. 1, pp. 9–14, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. C. Werner, “Modification of the classification of the eye changes of Graves' disease,” American Journal of Ophthalmology, vol. 83, no. 5, pp. 725–727, 1977. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Luchetti, G. Piccinini, and A. Mantovani, “Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA),” Clinical & Experimental Immunology, vol. 119, no. 1, pp. 196–202, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Planck, H. Parikh, H. Brorson et al., “Gene expression in Graves' ophthalmopathy and arm lymphedema: Similarities and differences,” Thyroid, vol. 21, no. 6, pp. 663–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Wang, S. J. Atkins, R. Fernando, R. L. Wei, and T. J. Smith, “Pentraxin-3 Is a TSH-inducible protein in human fibrocytes and orbital fibroblasts,” Endocrinology, vol. 156, no. 11, pp. 4336–4344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. S. C. G. Tseng, “HC-HA/PTX3 purified from amniotic membrane as novel regenerative matrix: Insight into relationship between inflammation and regeneration,” Investigative Ophthalmology & Visual Science, vol. 57, no. 5, pp. ORSFh1–ORSFh8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Zhang, Y. T. Zhu, S. Y. Chen, H. He, and S. C. G. Tseng, “Constitutive expression of pentraxin 3 (PTX3) protein by human amniotic membrane cells leads to formation of the heavy chain (HC)-hyaluronan (HA)-PTX3 complex,” The Journal of Biological Chemistry, vol. 289, no. 19, pp. 13531–13542, 2014. View at Publisher · View at Google Scholar · View at Scopus